My Testimony Before the ADCOM for AcelRex’s DSUVIA


On Friday, Oct. 12, 2018, AcelRex Pharmaceuticals, Inc. presented its case to the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (ADCOM) to discuss the approval of the new drug application (NDA) 209128 for DSUVIA™. DSUVIA is a small sufentanil pill deposited below the tongue with an applicator. It is…

Read More